Nanogen to Acquire Syn X Pharma in CA$16.3M Transaction

Feb 10, 2004

NEW YORK, Feb. 10 (GenomeWeb News) - Nanogen plans to acquire Syn X Pharma in an all-stock transaction, the company said today.

The transaction is valued at approximately CA$16.3 million ($12.3 million). Under the agreement, Nanogen will offer common shares to holders of Syn X common shares in a stock-for-stock exchange.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Mouse Fight

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Seeing the Interactions

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

This Week in Science

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

For Millions

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Main menu